Investment Rating - The report maintains an "Accumulate" rating for the company, indicating an expected relative performance increase of 5% to 15% over the next 6 to 12 months [9]. Core Viewpoints - The company has shown resilience in performance despite geopolitical risks, with steady growth in global sequencing installations [1]. - The core sequencing business is experiencing robust growth, with a significant increase in installed machines and market share, particularly in the domestic market [6]. - The company is positioned as a leader in the domestic sequencing market, benefiting from the ongoing trend of domestic substitution as competitors face challenges [6]. Financial Performance Summary - For 2024, the company reported revenue of 3.013 billion yuan, a year-on-year increase of 3.48%, and a net profit attributable to shareholders of -601 million yuan, a slight improvement of 1.10% year-on-year [3]. - The first quarter of 2025 saw a revenue decline of 14.26% year-on-year, with a net profit of -133 million yuan, reflecting a 33.67% increase compared to the previous year [3]. - The company’s revenue projections for 2025 to 2027 are 3.607 billion yuan, 4.500 billion yuan, and 5.597 billion yuan, respectively, with expected growth rates of 20%, 25%, and 24% [6]. Market Position and Strategy - The company achieved a historical high in new sales installations, with nearly 1,270 new machines sold in 2024, representing a 48.59% increase year-on-year [6]. - The global market share is approximately 7.1% based on revenue, and 28.2% based on new installations, indicating strong competitive positioning [6]. - The company is expanding its overseas presence with a marketing team of nearly 900 people, enhancing local support services to accelerate product adoption [6]. Cost and Efficiency Metrics - The company’s sales expense ratio for 2024 was 25.42%, a decrease of 3.16 percentage points year-on-year, while the management expense ratio increased by 1.83 percentage points to 19.98% [6]. - The gross margin for 2024 was 55.51%, down 3.96 percentage points year-on-year, primarily due to changes in product mix [6]. Future Outlook - The company is expected to continue benefiting from innovative product launches and global channel development, despite potential macroeconomic impacts on conventional business growth [6]. - The forecasted net profit for 2025 is -177 million yuan, with significant growth anticipated in subsequent years, reaching 182 million yuan by 2027 [6].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [4][23]. Core Views - The company has shown a strong performance in Q1 2025, with revenue reaching 759 million yuan, a year-on-year increase of 10.13% and a quarter-on-quarter increase of 8.69%. The net profit attributable to the parent company was 86.18 million yuan, up 112.70% year-on-year and 395.35% quarter-on-quarter [6]. - The report highlights that the company is approaching a performance inflection point, driven by robust growth in new business segments and significant improvements in profitability [3][6]. - The company is positioned as a leader in the raw material drug market, particularly in the low-price range of sartans, while non-sartan raw materials are identified as a core growth driver for the future [6]. Summary by Sections Financial Performance - For 2023, the company reported a revenue of 2,527.27 million yuan, with a year-on-year decline of 5.23%. However, projections for 2024 and beyond show a recovery with revenues expected to grow to 2,630.81 million yuan in 2024 and reaching 4,279.35 million yuan by 2027 [4][22]. - The net profit attributable to the parent company is forecasted to increase significantly from 27.36 million yuan in 2023 to 461 million yuan in 2027, reflecting a compound annual growth rate of 29.71% [4][22]. Business Segments - The report details that the non-sartan raw material segment achieved revenue of 189 million yuan in Q1 2025, marking a 57% year-on-year increase, indicating strong growth potential [6]. - The formulation business generated 80.77 million yuan in revenue, a 97% increase, with the number of approved formulations rising to 63, suggesting ongoing contributions to revenue growth [6]. Profitability Metrics - The gross margin for Q1 2025 was reported at 37.39%, an increase of 2.06 percentage points year-on-year, while the net margin reached 11.35%, up 5.47 percentage points year-on-year [6]. - The report anticipates that the company's gross margin will continue to improve, reaching 41.0% by 2027 [22]. Research and Development - R&D expenses for Q1 2025 were 53.45 million yuan, accounting for 7.04% of revenue, indicating a stable investment in innovation [6][22]. - The company plans to complete the process validation for 12 new raw material drug varieties by 2024, which is expected to drive future growth [6].

Investment Rating - The report maintains a "Buy" rating for Hisense Visual Technology, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [12]. Core Views - The company's revenue and profit are under short-term pressure, but the long-term growth logic remains unchanged. The expected revenue for 2025 is projected at 62,496 million yuan, with a year-on-year growth rate of 7% [3][8]. - The first quarter of 2025 showed a revenue of 13.4 billion yuan, a 5% increase year-on-year, and a net profit attributable to shareholders of 554 million yuan, a 19% increase, aligning with expectations [4][9]. - The company anticipates a recovery in export sales in Q2, driven by improved demand in Europe and emerging markets, despite a subdued performance in North America [5][6]. Financial Performance Summary - Revenue projections for the upcoming years are as follows: 58,530 million yuan in 2024, 62,496 million yuan in 2025, 67,048 million yuan in 2026, and 72,752 million yuan in 2027, with respective growth rates of 9%, 7%, 7%, and 9% [3]. - The net profit attributable to shareholders is expected to grow from 2,246 million yuan in 2024 to 3,206 million yuan in 2027, with growth rates of 7%, 13%, 12%, and 12% respectively [3][8]. - The earnings per share (EPS) is projected to increase from 1.72 yuan in 2024 to 2.46 yuan in 2027 [3][8]. Profitability and Margin Analysis - The gross margin for Q1 2025 was reported at 15.93%, with an expected improvement in profit margins due to government subsidies boosting domestic sales prices [6][8]. - The net profit margin for Q1 2025 was 4.1%, slightly lower than the peak of 5.2% in Q4 2024, but still at a historically high level [7][8]. - The report indicates that the company is focusing on structural upgrades to enhance profitability in the long term, with expectations of higher net profit growth in Q2 and Q3 of 2025 [8].

一般零售 | | | 执业证书编号：S0740524040004 Email：zhengch@zts.com.cn 执业证书编号：S0740523060001 Email：zhangji01@zts.com.cn 基本状况 | 总股本(百万股) | 638.34 | | --- | --- | | 流通股本(百万股) | 638.34 | | 市价(元) | 10.85 | | 市值(百万元) | 6,925.97 | | 流通市值(百万元) | 6,925.97 | 核心观点：本报告主要强调家悦烘焙逻辑，结合公司基本面改善的确定性较高，若家 悦烘焙出现较好的品牌势能，则家家悦有望成为较好赔率的投资标的。 请务必阅读正文之后的重要声明部分 新烘焙，新家悦 ——家家悦首次覆盖报告 股价与行业-市场走势对比 首次覆盖，给予"增持"评级。因公司在现制烘焙领域的尝试仍处于早期，本报告在 盈利预测时暂不考虑家悦烘焙远期成为独立品牌以及独立门店扩张带来的收入和利 润 增 量 。 预 计 公 司 25/26/27 年 收 入 分 别 为 185.66/192.58/200.66 亿 元 ， yoy+2%/+4%/+4% 。 ...

业绩稳健增长，至期光子营收大增 光学光电子 | 分析师：王芳 | | --- | | 执业证书编号：S0740521120002 | | Email：wangfang02@zts.com.cn | | 分析师：杨旭 | | 执业证书编号：S0740521120001 | | Email：yangxu01@zts.com.cn | | 分析师：张琼 | | 执业证书编号：S0740523070004 | | Email：zhangqiong@zts.com.cn | | 基本状况 | | | --- | --- | | 总股本(百万股) | 470.25 | | 流通股本(百万股) | 468.15 | | 市价(元) | 35.18 | | 市值(百万元) | 16,543.40 | | 流通市值(百万元) | 16,469.58 | 福晶科技（002222.SZ） 证券研究报告/公司点评报告 2025 年 05 月 07 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | - ...

Policy Adjustments - The central bank announced a 0.5 percentage point reduction in the reserve requirement ratio, expected to provide approximately 1 trillion yuan in long-term liquidity[3] - A policy interest rate cut of 0.1 percentage points was implemented, lowering the 7-day reverse repurchase rate from 1.5% to 1.4%[3] - The personal housing provident fund loan interest rate was reduced by 0.25 percentage points, with the five-year and above first home rate decreasing from 2.85% to 2.6%, saving residents over 20 billion yuan annually[4] Market Impact - The meeting's timing and the announcement of incremental policies exceeded market expectations, particularly the interest rate cut[5] - The stock market responded positively, with the Shanghai Composite Index rising by 0.8% to 3342.7 points, and the micro-cap index increasing by 1.2%[7] - Bond market yields showed mixed reactions, with the 1-year treasury yield decreasing by 1.75 basis points while the 10-year yield increased by 1.5 basis points[7] Economic Outlook - The incremental financial policies aim to stabilize the market and support consumption, small and micro enterprises, and the real estate sector[6] - Despite the positive market response, risks remain due to potential economic pressures from international trade tensions and weaker PMI data[6] - The report suggests that without further demand-side fiscal policies, the market may revert to focusing on fundamental economic conditions[7]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [5][11]. Core Views - The company's performance has been impacted by short-term factors, but share buybacks demonstrate confidence in future development [4]. - The company is a leading domestic automotive connector supplier with a diverse client base, including major global automotive parts suppliers [7]. - The company has increased its R&D investment, achieving breakthroughs in various technologies, and aims to expand its production capacity in the new energy connector sector [7]. Financial Summary - The company reported a revenue of 1,466 million yuan for 2024, a year-on-year increase of 34.46%, and a net profit of 73 million yuan, a year-on-year increase of 2.08% [7]. - The projected revenues for 2025, 2026, and 2027 are 1,863 million yuan, 2,348 million yuan, and 2,971 million yuan respectively, with growth rates of 27% and 26% [5][10]. - The projected net profits for 2025, 2026, and 2027 are 96 million yuan, 130 million yuan, and 141 million yuan respectively, with a significant growth rate of 31% in 2025 [5][10]. Business Segmentation - In 2024, the automotive product revenue reached 1,050 million yuan, a year-on-year increase of 48.04%, while mobile phone product revenue decreased by 2.94% to 258 million yuan [7]. - The company has successfully supplied products to renowned automotive brands and parts suppliers, indicating a strong market presence [7]. R&D and Market Strategy - The company has invested 85 million yuan in R&D, accounting for 5.79% of its revenue, with a year-on-year increase of 28.98% [7]. - The company is focusing on emerging fields such as low-altitude economy, robotics, and communication technologies, indicating a strategic shift towards innovation and market expansion [7].

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating an expected relative performance increase of 5% to 15% over the next 6 to 12 months [8]. Core Views - The company has confirmed a turning point in profitability, with Q1 2025 showing a positive net profit after a series of high revenue growth quarters [3][5]. - The company achieved a revenue of 320 million yuan in 2024, reflecting a year-on-year growth of 25.9%, and a net profit of -37 million yuan, which is an improvement of 25.7% year-on-year [5]. - In Q1 2025, the company reported a revenue of 91 million yuan, a year-on-year increase of 17.7%, and a net profit of 468 thousand yuan, marking a return to profitability [5]. Summary by Sections Financial Performance - The company has shown continuous revenue growth for 10 consecutive quarters, confirming a stable upward trend in its fundamentals [5]. - The projected revenues for 2025 to 2027 are 401 million yuan, 461 million yuan, and 515 million yuan respectively, with growth rates of 25% and 15% [3]. - The forecasted net profit for 2025 is 36 million yuan, with a significant increase of 196% year-on-year, followed by 73 million yuan in 2026 and 98 million yuan in 2027 [3]. Cost Management - In Q1 2025, the company's gross margin improved to 32.4%, an increase of 5.7 percentage points year-on-year [5]. - The company has successfully reduced its sales and management expenses, contributing to improved profitability [5]. Business Development - The company is expanding its K12 school operations and has established a new vocational education branch in Shandong [5]. - The high school class at Chaoyang Kevin School commenced in the fall of 2023, and a math specialty class was introduced at Haidian Kevin School in the fall of 2024 [5].

饰品 执业证书编号：S0740523110001 Email：suchang@zts.com.cn 周大生（002867.SZ） 证券研究报告/公司点评报告 2025 年 05 月 07 日 执业证书编号：S0740524040004 Email：zhengch@zts.com.cn | 基本状况 | | | --- | --- | | 总股本(百万股) | 1,095.93 | | 流通股本(百万股) | 1,089.55 | | 市价(元) | 13.27 | | 市值(百万元) | 14,542.94 | | 流通市值(百万元) | 14,458.32 | 1、《金价抑制需求，基本面短期承压》 2024-11-08 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：苏畅 | | 营业收入（百万元） | | 16,290 | 13,891 | 14 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [5][11]. Core Views - The company's performance has been impacted by short-term factors, but share buybacks demonstrate confidence in future growth [4]. - The company is a leading domestic automotive connector supplier with a diverse client base, including major global automotive parts suppliers [7]. - The company is actively investing in emerging fields such as low-altitude economy, robotics, and communications, indicating a broad space for domestic substitution in the medium to long term [7]. Financial Performance Summary - For 2024, the company reported revenue of 1.466 billion yuan, a year-on-year increase of 34.46%, and a net profit of 73 million yuan, a year-on-year increase of 2.08% [7]. - The first quarter of 2025 showed revenue of 350 million yuan, a year-on-year increase of 5.63%, but a net profit decrease of 25.25% [7]. - The company’s gross margin for the year was 22.32%, down 4.10% year-on-year, primarily due to rising material costs and intense competition [7]. Revenue and Profit Forecast - Revenue projections for 2025 to 2027 are 1.863 billion yuan, 2.348 billion yuan, and 2.971 billion yuan, respectively, with growth rates of 27% and 26% [5][10]. - Net profit forecasts for the same period are 96 million yuan, 130 million yuan, and 141 million yuan, with significant growth expected in 2025 [5][10]. R&D and Market Position - The company has increased its R&D investment to 85 million yuan, accounting for 5.79% of revenue, with a year-on-year growth of 28.98% [7]. - The company has developed various high-voltage and high-current connectors, covering applications in new energy vehicles, intelligent driving, and 5G communications [7]. Capital Allocation - The company adjusted its fundraising projects, reducing the investment in the "New Energy Vehicle Connector Project" from 400 million yuan to 250 million yuan, reallocating funds to enhance production capacity and R&D capabilities [7].